Short-Term Drop in Antibody Titer After the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults

Overview

Journal Vaccines (Basel)

Date 2022 May 28

PMID 35632564

Authors

Jonas Herzberg

Bastian Fischer

Heiko Becher

Ann-Kristin Becker

Human Honarpisheh

Salman Yousuf Guraya

Tim Strate

Cornelius Knabbe

Affiliations

Soon will be listed here.

Abstract

Little is known about the longevity of antibodies after a third dose of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (BioNTech/Pfizer, Mainz, Germany). Therefore, serum antibody levels were evaluated after a third dose of BNT162b2 in healthy adult healthcare workers in Germany. These antibody levels dropped significantly within a short period of 11 weeks from 4155.59 ± 2373.65 BAU/mL to 2389.10 ± 1433.90 BAU/mL, p-value < 0.001 but remained higher than after the second dose (611.92 ± 450.31 BAU/mL). To evaluate the quality of the humoral immune response, we additionally measured neutralizing antibodies, which also showed a small but significant decrease within this short period. These data underline the positive effect of a third dose of BNT162b2 concerning antibody re-induction but also shows a drop of Anti-SARS-CoV-2-IgG within a short span of time.

Citing Articles

Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.

Laquintana V, Mottini C, Marchesi F, Marcozzi B, Terrenato I, Sperandio E Front Immunol. 2024; 14:1221587.

PMID: 38343436 PMC: 10853639. DOI: 10.3389/fimmu.2023.1221587.

SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.

Franzese M, Coppola L, Silva R, Santini S, Cinquanta L, Ottomano C Front Immunol. 2022; 13:947187.

PMID: 36248864 PMC: 9566572. DOI: 10.3389/fimmu.2022.947187.

References

Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

Herzberg J, Vollmer T, Fischer B, Becher H, Becker A, Sahly H . Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital. Int J Infect Dis. 2020; 102:136-143. PMC: 7566663. DOI: 10.1016/j.ijid.2020.10.026. View

Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G . Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. J Infect. 2022; 84(6):795-813. PMC: 8993491. DOI: 10.1016/j.jinf.2022.04.018. View

Infantino M, Manfredi M, Stacchini L, Cosma C, Grossi V, Lari B . The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Clin Chem Lab Med. 2022; 60(6):934-940. DOI: 10.1515/cclm-2022-0170. View

Saciuk Y, Kertes J, Shamir Stein N, Ekka Zohar A . Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine. J Infect Dis. 2021; 225(1):30-33. PMC: 8689889. DOI: 10.1093/infdis/jiab556. View

Ducloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C . Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int. 2021; 100(3):702-704. PMC: 8243640. DOI: 10.1016/j.kint.2021.06.025. View

Herzberg J, Fischer B, Lindenkamp C, Becher H, Becker A, Honarpisheh H . Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study. Front Immunol. 2022; 13:839922. PMC: 8931311. DOI: 10.3389/fimmu.2022.839922. View

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, Ness A, Awwad M, Ghantous N . Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years. JAMA. 2021; 326(21):2203-2204. PMC: 8652594. DOI: 10.1001/jama.2021.19885. View

10.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

11.

Stumpf J, Tonnus W, Paliege A, Rettig R, Steglich A, Gembardt F . Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant. Transplantation. 2021; 105(11):e267-e269. PMC: 8549130. DOI: 10.1097/TP.0000000000003903. View

12.

Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, Fafi-Kremer S . Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA. 2021; . PMC: 8456389. DOI: 10.1001/jama.2021.12339. View

13.

Burki T . Fourth dose of COVID-19 vaccines in Israel. Lancet Respir Med. 2022; 10(2):e19. PMC: 8752098. DOI: 10.1016/S2213-2600(22)00010-8. View

14.

Yavuz E, Gunal O, Basbulut E, Sen A . SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. J Med Virol. 2022; 94(8):3768-3775. PMC: 9088656. DOI: 10.1002/jmv.27794. View

15.

Davidov Y, Indenbaum V, Tsaraf K, Cohen-Ezra O, Likhter M, Ben Yakov G . A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients. J Hepatol. 2022; 77(3):702-709. PMC: 9015954. DOI: 10.1016/j.jhep.2022.03.042. View

16.

Fischer B, Lichtenberg C, Muller L, Timm J, Fischer J, Knabbe C . A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories. J Clin Virol. 2021; 144:104984. PMC: 8444349. DOI: 10.1016/j.jcv.2021.104984. View

17.

Stubblefield W, Talbot H, Feldstein L, Tenforde M, Rasheed M, Mills L . Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19-Nashville, Tennessee. Clin Infect Dis. 2020; 72(9):1645-1648. PMC: 7454447. DOI: 10.1093/cid/ciaa936. View

18.

Bar-On Y, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N . Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021; 385(15):1393-1400. PMC: 8461568. DOI: 10.1056/NEJMoa2114255. View

19.

Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10:100208. PMC: 8418937. DOI: 10.1016/j.lanepe.2021.100208. View